Research Scholar
CohereFull Time
Internship
Candidates must possess a Bachelor's degree in Computer Science, Engineering, or a related field, coupled with over 7 years of industry experience in AI, machine learning, or similar roles, demonstrating a history of successfully implementing and deploying AI models in production. Proficiency in Python and C++, deep expertise in frameworks like PyTorch/Jax, a strong grasp of deep learning fundamentals including neural network architectures, optimization techniques, and evaluation metrics, and experience with distributed training and inference of large-scale AI models on thousands of GPUs using DDP, FSDP, etc., are essential. Experience with performance optimization of large-scale AI models, effective communication and collaboration skills for fast-paced, multidisciplinary team environments, and experience in solving complex problems by comparing alternative solutions, tradeoffs, and diverse viewpoints are also required. Preferred qualifications include a publication track record at top AI conferences, experience working cross-functionally, familiarity with different GPU architectures, cloud environments, low-level hardware optimization, and custom CUDA kernels, as well as contributions to open-source projects.
The Senior/Staff Research Engineer will drive the development of state-of-the-art AI models for drug discovery tasks, utilizing deep learning frameworks and scaling distributed training of large AI models on GPUs. Responsibilities include profiling and optimizing AI models for both training and inference, staying current with AI and machine learning advancements to identify innovation opportunities, and contributing to technical documentation, reports, and presentations. This role also entails providing deep technical leadership in the development and optimization of core AI models that power the company's drug discovery initiatives.
Develops therapies for autoimmune diseases
Abata Therapeutics develops therapies for autoimmune diseases, focusing on type 1 diabetes. Their main product, ABA 201, is a Treg cell therapy aimed at patients with some remaining beta cell function. This therapy works by utilizing regulatory T cells to improve patient outcomes. Unlike many competitors, Abata targets a specific niche within the autoimmune disease market and collaborates with partners like ElevateBio for process development and manufacturing. The company's goal is to transform treatment options for autoimmune diseases through advanced research and development.